Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03451396 · ClinicalTrials.gov registry record · Phase 4
Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms
A Phase 4 study of Dry Eye, sponsored by Lifelong Vision Foundation.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03451396: Completed Phase 4 study of Dry Eye, sponsored by Lifelong Vision Foundation.
NCT03451396 is a Phase 4 study of Dry Eye that has completed, run by Lifelong Vision Foundation. The registered enrollment target is 30 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03451396, a Phase 4 study of Dry Eye, has completed, sponsored by Lifelong Vision Foundation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.
Primary Outcome
Number of participants with an improvement in Tear Osmolarity measured using the Tear Osmolarity score treated with Lifitegrast.
Conditions Studied
Interventions
- DRUG Lifitegrast
Study Locations (1)
Missouri
- Lifelong Vision Foundation - Chesterfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2016-12-12 |
| Est. Completion | 2018-03-15 |
| Phase | Phase 4 |
What the finished NCT03451396 record still lists
NCT03451396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which Lifitegrast is the first listed.
NCT03451396 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT03451396 about?
NCT03451396 is a clinical study titled "Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms". To determine whether a fall in tear osmolarity precedes improvement in symptoms and signs of dry eye in dry eye patients treated topically with 5% lifitegrast drops for 3 months.
What is the current status of trial NCT03451396?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2016-12-12. Estimated completion is 2018-03-15.
What conditions does trial NCT03451396 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT03451396?
The interventions under investigation include: Lifitegrast (DRUG).
Who is sponsoring clinical trial NCT03451396?
This trial is sponsored by Lifelong Vision Foundation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03451396 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03451396's enrollment target sits among peer trials
30 31st of 41 higher than 9 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI